Biomaterials Translational ›› 2021, Vol. 2 ›› Issue (1): 30-42.doi: 10.3877/cma.j.issn.2096-112X.2021.01.005

• REVIEW • Previous Articles     Next Articles

A biomaterials viewpoint for the 2020 SARS-CoV-2 vaccine development

Isak Jatoi, Jingyu Fan*()   

  1. Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, USA
  • Received:2021-03-03 Revised:2021-03-18 Accepted:2021-03-19 Online:2021-03-31 Published:2021-03-28
  • Contact: Jingyu Fan E-mail:jingyu@email.sc.edu


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused a considerable loss of life, morbidity, and economic distress since its emergence in late 2019. In response to the novel virus, public and private institutions around the world have utilized novel technologies to develop a vaccine in the hopes of building herd immunity and ending the pandemic. This review provides an overview of mechanisms and available data on the nascent vaccine technologies undergoing clinical trials to combat SARS-CoV-2, namely, those using protein subunits, viral vectors, mRNA, and DNA. Furthermore, we discuss the potential uses of biomaterials in improving the immunogenicity and safety of these vaccine technologies with the goal of improving upon newly-available technologies to combat future SARS-CoV-2 strains and other emerging viral pathogens.

Key words: biomaterials, COVID-19, nanomaterials, SARS-CoV-2, vaccine